GCP
AARD

GSA Capital Partners’s Aardvark Therapeutics AARD Stock Holding History

GSA Capital Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,085
Closed -$102K – 2263
2026
Q1 		$102K Sell
27,085
-8,839
-25% -$91.6K 0.01% 1561
2025
Q4 		$472K Buy
+35,924
New +$448K 0.04% 855

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

GSA Capital Partners's AARD Position: Q2 2026 in Review

GSA Capital Partners sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 27,085 shares — an estimated $102K sold.

GSA Capital Partners first reported a position in AARD in Q4 2025 and held it in 2 quarters. The position peaked at $472K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • GSA Capital Partners reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 27,085 Aardvark Therapeutics shares in Q2 2026, an estimated $102K.
  • GSA Capital Partners first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 2 quarters.
  • GSA Capital Partners's Aardvark Therapeutics position peaked at $472K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.